Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29603301 | 1.00 | NPSR1 (0.53) | NPSR1CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL1813853 | 0.91 | TEAD1 (0.51) | NPSR1CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL9798371 | 0.88 | LTA4H (0.54) | NPSR1CYP1A2CYP2C9CYP2C19TEAD1 | |
| SCHEMBL3553556 | 0.87 | LTA4H (0.52) | NPSR1CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL27579381 | 0.84 | LTA4H (0.59) | NPSR1CYP1A2CYP2C9CYP2C19TEAD1 | |
| SCHEMBL9546526 | 0.82 | L3MBTL1 (0.55) | NPSR1CYP1A2CYP2C9CYP2C19TEAD1 | |
| SCHEMBL4661 | 0.82 | CA1 (0.57) | NPSR1KIF11ALDH1A1MAPTTSHR | |
| SCHEMBL29824423 | 0.82 | CA1 (0.57) | NPSR1KIF11ALDH1A1MAPTTSHR | |
| SCHEMBL457828 | 0.82 | MAOB (0.54) | ALDH1A1MAPTABCG2MAPK1SLC6A2 | |
| SCHEMBL29623441 | 0.80 | NPSR1 (0.56) | NPSR1CYP1A2CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577208-B2 | TEAD inhibitors and uses thereof | EHE Foundation (US) | 2026-03-17 | — | — | US | disclosed |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2024-03-14 | — | — | US | disclosed |
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-11458149-B1 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3976192-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243423-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2020243415-A2 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-1993024600-A1 | OXIDATION-RESISTANT CYCLOPHOSPHAZENE FLUID INCLUDING TRIARYLPHOSPHINE OR PHOSPHINE OXIDE | THE DOW CHEMICAL COMPANY (US) | 1993-12-09 | — | — | WO | disclosed |
| US-5194652-A | High temperature lubricants, hydraulic fluids; jet aircraft, turbines, diesel engines | THE DOW CHEMICAL COMPANY (US) | 1993-03-16 | — | — | US | disclosed |
| US-5066409-A | Novel aryl ether sulfones | THE DOW CHEMICAL COMPANY (US) | 1991-11-19 | — | — | US | disclosed |
| US-4870213-A | Aryloxyperfluoroalkyl arenes | THE DOW CHEMICAL COMPANY (US) | 1989-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | NPSR1 4803/4885CYP1A2 1283/4885CYP2C9 1484/4885 |
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | NPSR1 4803/4885CYP1A2 1283/4885CYP2C9 1484/4885 |
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | NPSR1 4803/4885CYP1A2 1283/4885CYP2C9 1484/4885 |
| US-20240083854-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | NPSR1 4803/4885CYP1A2 1283/4885CYP2C9 1484/4885 |
| US-11458149-B1 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | NPSR1 4803/4885CYP1A2 1283/4885CYP2C9 1484/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | NPSR1 4803/4885CYP1A2 1283/4885CYP2C9 1484/4885 |
| US-12577208-B2 | TEAD inhibitors and uses thereof | BRCA1, BRAF, MEN1 | NPSR1 3261/4885CYP1A2 751/4885CYP2C9 388/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | NPSR1 4803/4885CYP1A2 1283/4885CYP2C9 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.